O'Brien Stephen Paul 4

What Happened

• Stephen Paul O'Brien, Principal Accounting Officer of Tvardi Therapeutics (TVRD), was granted a derivative award of 15,000 shares on January 29, 2026. The reported acquisition price is $0.00 per share (derivative security), indicating a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-29
• Grant: 15,000 shares (derivative) at $0.00 per share
• Filing date: 2026-02-02 (filed within two business days of the transaction)
• Shares owned after transaction: not specified in the Form 4 summary provided
• Footnote: Shares vest in equal monthly installments over 48 months beginning January 29, 2026, subject to continuous service

Context

• This is a compensation grant (award of derivative securities) that vests over time to incentivize retention; it is not an immediate purchase or sale and does not produce cash proceeds or indicate a market sale.